甲状腺髓样癌中Ki67和降钙素的表达及临床意义

冯佳佳; 王家东

doi:10.13201/j.issn.1001-1781.2014.24.004

甲状腺髓样癌中Ki67和降钙素的表达及临床意义

冯佳佳,
王家东^,

- 上海交通大学医学院附属仁济医院头颈外科(上海, 200001)

详细信息

通讯作者: 王家东,E-mail:drjiadongw@aliyun.com

中图分类号: R736.1

收稿日期: 2014-09-11

Expression and clinical significance of Ki67 and calcitonin in medullary thyroid carcinoma

FENG Jiajia,
WANG Jiadong^,

- Department of Head and Neck Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200001, China

More Information

Corresponding author: WANG Jiadong, E-mail: drjiadongw@aliyun.com

Received Date: 11 September 2014

摘要

摘要: 目的:探讨增殖细胞相关抗原(Ki67)和降钙素在甲状腺髓样癌组织中的表达及其临床意义。方法:采用免疫组织化学SP法分别检测44例甲状腺髓样癌组织和20例癌旁组织中Ki67和降钙素的表达水平。结果:44例甲状腺髓样癌组织中Ki67和降钙素的表达率为86.36%(38/44)和100.00%(44/44),明显高于其在癌旁组织中的表达率0%(0/20)和20%(4/20)(P<0.01)。Ki67增殖指数和降钙素与患者肿瘤大小、临床分期和淋巴结转移有关(P<0.05),而与患者年龄、性别无关(P>0.05)。在甲状腺髓样癌中Ki67和降钙素的表达水平无显著相关性(P=0.081)。结论:Ki67和降钙素高表达与甲状腺髓样癌的发生、发展及浸润转移有关,可作为判断甲状腺髓样癌生物学行为的重要指标。
- 甲状腺肿瘤 /
- 癌 /
- 髓样 /
- Ki67 /
- 降钙素
Abstract: Objective:To investigate the expression and clinical significance of Ki67 and calcitonin in medullary thyroid carcinoma(MTC).Method:The expression level of Ki67 and calcitonin was studied in 44 cases of medullary thyroid carcinoma tissue and 20 cases of adjacent nontumor tissue by SP immunohistochemistry. Result:The positive expression of Ki67 and calcitonin in medullary thyroid carcinoma tissue were 86.36%(38/44) and 100.00% (44/44) respectively.There was a significant difference between carcinoma and normal thyroid tissue (P<0.01).The overexpression of Ki67 and calcitonin in medullary thyroid carcinoma had no relationship with gender and age of patients,but had relationship with size of tumor,clinical staging and lymph node metastasis (P<0.05).Meanwhile, Ki67 and calcitonon had no significant correlation with each other.Conclusion:The overexpression of Ki67 and calcitonin may play important role in occurrence,development and metastasis of medullary thyroid carcinoma.It may be used as an important judgement for the biological behavior of medullary thyroid carcinoma.
- thyroid neoplasms /
- carcinoma /
- medullary /
- Ki67 /
- calcitonin

HTML全文

参考文献(20)

[1]	KLOOS R T, ENG C, EVANS D B, et al.Medullary thyroid cancer:management guidelines of the American Thyroid Association[J].Thyroid, 2009, 19:565-612.
[2]	TISELL L E, DILLEY W G, WELLS S A.Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels[J].Surgery, 1996, 119:34-39.
[3]	RINK T, TRUONG P N, SCHROTH H J, et al.Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease[J].Thyroid, 2009, 19:327-332.
[4]	SCHEUBA C, KASERER K, MORITZ A, et al.Sporadic hypercalcitoninemia:clinical and therapeutic consequences[J].Endocr Relat Cancer, 2009, 16:243-253.
[5]	赵自然, 康维明.MTC外科诊治[J].中华临床医师杂志, 2012, 6 (5):126-128.
[6]	ESFANDIARI N H, HUGHES D T, YIN H, et al.The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer[J].J Clin Endocrinol Metab, 2014, 99:448-454.
[7]	ROY M, CHEN H, SIPPEL R S.Current understanding and management of medullary thyroid cancer[J].Oncologist, 2013, 18:1093-1100.
[8]	WELCH K, MCHENRY C R.Selective lateral compartment neck dissection for thyroid cancer[J].J Surg Res, 2013, 184:193-199.
[9]	KWON H, KIM W G, CHOI Y M, et al.A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma[J].Clin Endocrinol (Oxf), 2014.
[10]	TOLEDO S P, LOURENCO D M, SANTOS M A, et al.Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma[J].Clinics (Sao Paulo), 2009, 64:699-706.
[11]	GIOVANELLA L, CRIPPA S, CARIANI L.Serum calcitonin-negative medullary thyroid carcinoma:role of CgA and CEA as complementary markers[J].Int J Biol Markers, 2008, 23:129-131.
[12]	SAWHNEY H, HALL P A.Ki67——structure, function, and new antibodies[J].J Pathol, 1992, 168:161-162.
[13]	杨欢, 陈晓耕, 陈新, 等.乳腺浸润性导管癌组织Ki-67表达及其分子型的意义[J].中华肿瘤防治杂志, 2012, 19 (3):212-216.
[14]	DE AZAMBUJA E, CARDOSO F, DE CASTRO G, et al.Ki-67as prognostic marker in early breast cancer:a meta-analysis of published studies involving 12, 155patients[J].Br J Cancer, 2007, 96:1504-1513.
[15]	DOWSETT M, NIELSEN T O, A'HERN R, et al.Assessment of Ki67in breast cancer:recommendations from the International Ki67in Breast Cancer working group[J].J Natl Cancer Inst, 2011, 103:1656-1664.
[16]	RICHARDSEN E, UGLEHUS R D, DUE J, et al.COX-2is overexpressed in primary prostate cancer with metastatic potential and may predict survival.A comparison study between COX-2, TGF-beta, IL-10and Ki67[J].Cancer Epidemiol, 2010, 34:316-322.
[17]	ITO Y, MIYAUCHI A, KAKUDO K, et al.Prognostic significance of ki-67labeling index in papillary thyroid carcinoma[J].World J Surg, 2010, 34:3015-3021.
[18]	HE W L, LI Y H, YANG D J, et al.Combined evaluation of centromere protein H and Ki-67as prognostic biomarker for patients with gastric carcinoma[J].Eur J Surg Oncol, 2013, 39:141-149.
[19]	SCOAZEC J Y, COUVELARD A, POUR LE RESEAU T.The new WHO classification of digestive neuroendocrine tumors[J].Ann Pathol, 2011, 31:88-92.
[20]	SALAMA A, BADAWY O, MOKHTAR N.Ki-67is a powerful tool for grading neuroendocrine tumors among Egyptian patients:a 10-year experience[J].J Cancer Res Clin Oncol, 2014, 140:653-661.